| November 03, 2009 |
Merck and Schering-Plough to Complete Merger Today|
New Merck Will Begin Combined Operations Tomorrow
Global Health Care Leader Poised for Sustainable Growth Through
Innovations for Patients
WHITEHOUSE STATION, N.J. & KENILWORTH, N.J.--(BUSINESS WIRE)--Nov. 3, 2009--
Merck & Co., Inc. (NYSE: MRK) and Schering-Plough Corporation (NYSE:
SGP) today announced that they will complete their merger shortly
after 4:00PM ET today. The companies will begin combined operations
tomorrow, No... |
|
 |
| November 02, 2009 |
Schering-Plough Reports Potent Antiviral Activity With Narlaprevir (SCH 900518), an Investigational, Once-Daily Protease Inhibitor for Hepatitis C| Interim results of Phase IIa NEXT-I study presented at American Association for the Study of Liver Diseases (AASLD) Annual Meeting
BOSTON, Nov. 2 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE: SGP) today reported that interim results from an ongoing Phase IIa study of narlaprevir (SCH 900518), its investigational, once-daily protease inhibitor, demonstrated potent antiviral activity in treatment-naive patients with chronic hepatitis C virus (HCV) genotype 1. In the lead-in ... |
|
|
| November 02, 2009 |
Schering-Plough Announces Sponsorship of Rabies-Control Projects in India| Program Focus: Community Education and Mass Vaccination of Dogs in 10 Villages
KENILWORTH, N.J., Nov. 2 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE: SGP) today announced it has initiated sponsorship of two projects in India to reduce the incidence of human and animal rabies through improved educational awareness and mass vaccination of dogs. The company will donate $200,000 and rabies vaccine from Intervet/Schering-Plough as well as share expertise with partners to support... |
|
|
| November 02, 2009 |
Investigational Sublingual Allergy Immunotherapy Tablet Meets Primary Endpoint in a Study of Adult Subjects With a History of Grass Pollen Allergies| KENILWORTH, N.J., Nov 02, 2009 /PRNewswire-FirstCall via COMTEX/ -- Schering-Plough Corporation (NYSE: SGP) today announced that its investigational sublingual Grass (Phleum Pratense) Allergy Immunotherapy Tablet (AIT) has met the primary endpoint in a Phase III study of adult subjects in the U.S. with a history of grass pollen induced rhinoconjunctivitis with or without asthma. The investigational Grass AIT treatment is designed to work by inducing a protective immune response against grass po... |
|
|
| November 01, 2009 |
Data Supporting Boceprevir Response Guided Therapy Presented at American Association for the Study of Liver Diseases (AASLD) Annual Meeting|
BOSTON, Nov. 1 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE: SGP) today reported two data presentations supporting response guided therapy with boceprevir combination therapy in patients with chronic hepatitis C virus (HCV) genotype 1. These retrospective analyses were presented at the American Association for the Study of Liver Diseases (AASLD) Annual Meeting in Boston, Oct. 30-Nov. 3.
Boceprevir is an investigational HCV protease inhibitor. Phase III registration studie... |
|
|
| October 30, 2009 |
U.S. Food and Drug Administration Issues Complete Response Letter Regarding PEGINTRON(R) for Malignant Melanoma|
KENILWORTH, N.J., Oct. 30 /PRNewswire-FirstCall/ -- Schering-Plough Corp. (NYSE: SGP) announced today the U.S. Food and Drug Administration (FDA) has issued a complete response letter to the company's supplemental Biologics License Application regarding PEGINTRON® (pegylated interferon alfa-2b) for the adjuvant treatment of patients with stage III malignant melanoma after complete lymphadenectomy.
Schering-Plough will work closely with FDA to respond to outstanding concerns related to the ... |
|
|
| October 29, 2009 |
Merck and Schering-Plough Receive Approvals From U.S. Federal Trade Commission, Swiss Competition Commission and Canadian Competition Bureau for Merger| WHITEHOUSE STATION, N.J. & KENILWORTH, N.J.--(BUSINESS WIRE)--Merck & Co., Inc. (NYSE: MRK - News) and Schering-Plough Corporation (NYSE: SGP - News) today announced that they have received clearance from the U.S.
Federal Trade Commission (FTC), the Swiss Competition Commission and the
Canadian Competition Bureau for their proposed merger.
The companies said that the FTC terminated the waiting period under the
Hart-Scott-... |
|
|
